ArticleVirology journal2012
Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein.
Article in Virology journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.PloS one · 2013Trial
- A vaccine platform targeting lung-resident memory CD4Nature communications · 2024Article
- M2e-Based Influenza Vaccines with Nucleoprotein: A Review.Vaccines · 2021Review
- Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.Emerging microbes & infections · 2020Article
- Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.Frontiers in immunology · 2019Article
- Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates.PloS one · 2017Article
- In Silico Analysis of HA2/Mx Chimera Peptide for Developing an Adjuvanted Vaccine to Induce Immune Responses Against Influenza Viruses.Advanced pharmaceutical bulletin · 2015Article
- Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.Plant cell reports · 2015Article
- Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.Virologica Sinica · 2015Article
- Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Clinical and vaccine immunology : CVI · 2015Article
- Advancements in the development of subunit influenza vaccines.Microbes and infection · 2015Review
- Development of cross-protective influenza a vaccines based on cellular responses.Frontiers in immunology · 2015Review
- Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice.PloS one · 2014Article
- Improvement Efficacy of Influenza Nanovaccine in Combination with Hemokinin-1 Molecular Adjuvant.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe highly conserved nucleoprotein (NP) is an internal protein of influenza virus and is capable of inducing cross-protective immunity against different influenza A viruses, making it a main target of universal influenza vaccine. In current study, we characterized the immune response induced by DNA prime-intranasal protein boost strategy based on NP (A/PR/8/34, H1N1) in mouse model, and evaluated its protection ability against a lethal dose challenge of influenza virus.
resultsThe intranasal boost with recombinant NP (rNP) protein could effectively enhance the pre-immune response induced by the NP DNA vaccine in mice. Compared to the vaccination with NP DNA or rNP protein alone, the prime-boost strategy increased the level of NP specific serum antibody, enhanced the T cell immune response, and relatively induced more mucosal IgA antibody. The overall immune response induced by this heterologous prime-boost regimen was Th-1-biased. Furthermore, the immune response in mice induced by this strategy provided not only protection against the homologous virus but also cross-protection against a heterosubtypic H9N2 strain.
conclusionsThe NP DNA prime-intranasal protein boost strategy may provide an effective strategy for universal influenza vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.